A5079550043- Ovarian cancer diagnosis and treatment
- Intraperitoneal and Appendiceal Malignancies
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Endometrial and Cervical Cancer Treatments
- Toxin Mechanisms and Immunotoxins
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Childhood Cancer Survivors' Quality of Life
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Statistical Methods in Clinical Trials
- Brain Metastases and Treatment
- Multiple and Secondary Primary Cancers
- Neurological Complications and Syndromes
- Biosimilars and Bioanalytical Methods
- Reproductive Biology and Fertility
- Neutropenia and Cancer Infections
- Cancer, Stress, Anesthesia, and Immune Response
Centre Hospitalier Universitaire de Saint-Étienne
2023-2025
Hospices Civils de Lyon
2019-2024
Centre Léon Bérard
2020-2024
Université Claude Bernard Lyon 1
2019-2024
Institute Cancer De La Loire Lucien Neuwirth
2024
Centre de Recherche en Cancérologie de Lyon
2021-2024
Hôpital Nord
2024
Société Francophone du Diabète
2022
Hôpital Lyon Sud
2019-2022
Immunotherapy has been widely applied to treat metastatic renal cell cancer patients. Managing the side effects of immunotherapy can be a challenge. Here, we describe rare presentation cutaneous anguillulosis during immunotherapy. The patient experienced rash eruption after receiving for cancer. diagnosis skin toxicity caused by was rejected failure treatment cortisone. travelling history and laboratory test confirmed presence infection. A established. Satisfactory with ivermectin achieved...
Early-phase clinical trials (EPCT) represent an important part of innovations in medical oncology and a valuable therapeutic option for patients with metastatic cancers, particularly the era precision medicine. Nevertheless, adult patients' participation is low, ranging from 2% to 8% worldwide, unequal access, up 40% risk early discontinuation EPCT, mostly due cancer-related complications. We review tools initiatives increase orientation access phase cancer trials, limit discontinuation. New...
It remains unclear whether immune-related adverse events (irAEs) and glucocorticoid use could impact long-term outcomes in patients treated for solid tumors with immune checkpoint inhibitors (ICI). All a single-agent ICI any advanced cancer were included this retrospective unicentric study. The objectives to assess the of grade ≥3 irAEs, interruption immunotherapy on progression-free survival (PFS) overall (OS). In 828-patient cohort, first occurrence irAEs had no significant PFS or OS....
TB in Europe are available since 2018 and widely prescribed. However, no data have ever been reported regarding their efficacy tolerance combination with pertuzumab chemotherap. Methodology: The observational PErtuzumab – TRAstuzumab (PETRA) study prospectively included patients Her 2-positive MBC receiving CT + P TB, whatever the EMA-approved product. main objectives were safety efficacy. Between Feb 3, 2021 Jul 31, 2023, 110 from 21 centers included: median age 58.5 [50.0 72.0], PS 0: 38.7...
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be synergistic with (IP) immunotherapy by increasing tumor antigen expression mutational load. We assessed the feasibility safety of IP nivolumab following complete CRS HIPEC in pretreated patients recurrent ovarian cancer (ClinicalTrials.gov identifier: NCT03959761).
Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number metastatic sites (MS) remains unclear patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess prognostic LM MS on progression-free survival (PFS) overall (OS) a large single-arm retrospective multicentric cohort (IMMUCARE) anti-PD(L)-1 for solid tumors. Results: A total 759 were enrolled from January 2012 October 2018. The primary...
Objectives: To assess how physicians and surgeons carried out malnutrition screening follow-up for patients with lung cancer.Materials methods: We an expert opinion survey in France using anonymous self-administered online questionnaire.Results: In 2017, 206 practitioners responded, of which 60.7% were pulmonologists, 17.4% thoracic surgeons, 11.2% oncologists, 10.7% radiotherapists. At initial diagnosis, 79.3% recorded patients’ percentage weight loss. During examinations, 67.5% this data...
e15029 Background: Nucleosomes (DNA wound around histone proteins) were reported as potential cancer biomarkers (1). The links between circulating nucleosomes and clinical endpoints in advanced ovarian (OC) patients treated with neo-adjuvant chemotherapy (NACT) +/- interval debulking surgery (IDS) retrospectively assessed the randomized phase II CHIVA trial (2). Methods: diagnostic concentration longitudinal kinetics of 2 (H3K27 H3K36, log-scale) investigated at baseline, during NACT, after...
<p>Kinetics of plasmatic nucleosomes and CA125</p>
<p>Kinetics of peritoneal nucleosomes and CA125</p>
<p>Comprehensive protocol of the study</p>